Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Comorbid substance abuse in first-episode schizophrenia: effects on cognition and psychopathology in the EUFEST study.

Wobrock T, Falkai P, Schneider-Axmann T, Hasan A, Galderisi S, Davidson M, Kahn RS, Derks EM, Boter H, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Gaebel W, Fleischhacker WW; EUFEST study group.

Schizophr Res. 2013 Jun;147(1):132-139. doi: 10.1016/j.schres.2013.03.001. Epub 2013 Mar 26.

PMID:
23537477
2.

Correlates of cognitive impairment in first episode schizophrenia: the EUFEST study.

Galderisi S, Davidson M, Kahn RS, Mucci A, Boter H, Gheorghe MD, Rybakowski JK, Libiger J, Dollfus S, López-Ibor JJ, Peuskens J, Hranov LG, Fleischhacker WW; EUFEST group.

Schizophr Res. 2009 Dec;115(2-3):104-14. doi: 10.1016/j.schres.2009.09.022. Epub 2009 Oct 12.

PMID:
19822407
3.

Profiling cognitive impairment in treatment-resistant schizophrenia patients.

Frydecka D, Beszłej JA, Gościmski P, Kiejna A, Misiak B.

Psychiatry Res. 2016 Jan 30;235:133-8. doi: 10.1016/j.psychres.2015.11.028. Epub 2015 Nov 18.

PMID:
26706131
4.

Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia.

Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P, Caspari D.

Eur Arch Psychiatry Clin Neurosci. 2007 Jun;257(4):203-10. Epub 2006 Nov 25.

PMID:
17131214
5.

Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).

Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet IP, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS.

Am J Psychiatry. 2009 Jun;166(6):675-82. doi: 10.1176/appi.ajp.2008.08060806. Epub 2009 Apr 15. Erratum in: Am J Psychiatry. 2009 Jun;166(6):731.

PMID:
19369319
6.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
7.
8.

First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.

Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS; HGDH Research Group.

Schizophr Res. 2004 Feb 1;66(2-3):125-35.

PMID:
15061244
9.

Executive function in schizophrenia: influence of substance use disorder history.

Rodriguez-Jimenez R, Bagney A, Martinez-Gras I, Ponce G, Sanchez-Morla EM, Aragües M, Rubio G, Jimenez-Arriero MA, Santos JL, Palomo T; PARG.

Schizophr Res. 2010 May;118(1-3):34-40. doi: 10.1016/j.schres.2009.09.025. Epub 2009 Oct 25.

PMID:
19854622
10.

Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.

Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S.

J Clin Psychiatry. 1991 Jan;52(1):26-30.

PMID:
1671032
11.

Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis.

Potvin S, Joyal CC, Pelletier J, Stip E.

Schizophr Res. 2008 Mar;100(1-3):242-51. Epub 2007 Jul 5.

PMID:
17614260
12.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
13.
14.

Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.

Smith RC, Jin H, Li C, Bark N, Shekhar A, Dwivedi S, Mortiere C, Lohr J, Hu Q, Davis JM.

Schizophr Res. 2013 Jan;143(1):18-24. doi: 10.1016/j.schres.2012.10.023. Epub 2012 Nov 29.

PMID:
23200554
15.

Does substance use disorder affect clinical expression in first-hospitalization patients with schizophrenia? Analysis of a prospective cohort.

Picci RL, Versino E, Oliva F, Giaretto RM, Ostacoli L, Trivelli F, Venturello S, Furlan PM.

Psychiatry Res. 2013 Dec 30;210(3):780-6. doi: 10.1016/j.psychres.2013.08.043. Epub 2013 Sep 18.

16.

Psychopathology and Wisconsin Card Sorting Test performance in male schizophrenic patients: influence of dual diagnosis.

Rodriguez-Jimenez R, Aragües M, Jimenez-Arriero MA, Ponce G, Martinez I, Hoenicka J, Rubio G, Palomo T; Psychosis and Addictions Research Group (PARG).

Psychopathology. 2008;41(1):58-64. Epub 2007 Nov 1.

PMID:
17975329
17.

Evidence for an agitated-aggressive syndrome in early-onset psychosis correlated with antisocial personality disorder, forensic history, and substance use disorder.

Huber CG, Hochstrasser L, Meister K, Schimmelmann BG, Lambert M.

Schizophr Res. 2016 Aug;175(1-3):198-203. doi: 10.1016/j.schres.2016.04.027. Epub 2016 Apr 23.

PMID:
27117676
18.

Cannabis abuse is associated with decision-making impairment among first-episode patients with schizophrenia-spectrum psychosis.

Mata I, Rodríguez-Sánchez JM, Pelayo-Terán JM, Pérez-Iglesias R, González-Blanch C, Ramírez-Bonilla M, Martínez-García O, Vázquez-Barquero JL, Crespo-Facorro B.

Psychol Med. 2008 Sep;38(9):1257-66. Epub 2007 Nov 16.

PMID:
18005495
19.

[Factors related to suicide attempts in a Tunisian sample of patients with schizophrenia].

Bouhlel S, M'solly M, Benhawala S, Jones Y, El-Hechmi Z.

Encephale. 2013 Feb;39(1):6-12. doi: 10.1016/j.encep.2012.06.003. Epub 2012 Sep 25. French.

PMID:
23095582
20.

The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.

Good KP, Rabinowitz J, Whitehorn D, Harvey PD, DeSmedt G, Kopala LC.

Schizophr Res. 2004 May 1;68(1):11-9.

PMID:
15037335

Supplemental Content

Support Center